Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

•Addition of ibrutinib to nab-paclitaxel/gemcitabine did not improve efficacy outcomes for pancreatic ductal adenocarcinoma.•Primary endpoints—overall survival and investigator-assessed progression-free survival—were not met in this phase III study.•Ibrutinib treatment led to less time on treatment and lower cumulative dose for all agents compared with placebo treatment.•Reported safety was consistent with the known profiles for ibrutinib and nab-paclitaxel/gemcitabine.